Short answer: It is a proposed, per-claim settlement of existing ovarian cancer talc lawsuits. J&J committed $5.5 billion, conditioned on participation by at least 95% of remaining claims, with up to $3 billion paid in 2027 and nothing more due before 2028.
Reporting on the deal says it assigns values to qualifying claims rather than setting a hard cap, and plaintiffs’ counsel who negotiated it said the total could exceed $5.5 billion depending on participation. This is J&J’s fourth attempt to end the litigation; three earlier efforts used subsidiary bankruptcies that courts rejected.
- Covered: pending ovarian cancer claims in federal MDL 2738 and related state courts.
- Not covered: future claims, and mesothelioma lawsuits, which are resolved separately.
- Status: not yet in effect. Reported participation of about 87.5% is short of the 95% condition.
- Not public: the payment grid and what any individual will receive.
Questions about your own claim? Start a free, confidential case review.
SourcesJ&J talc dealFox Business / Reuters, 27 Jul 2026Settlement terms summaryExpert InstituteParticipation reportLawsuit Information Center, Nov 2026


